The study intends to enrol a total of 40 healthy participants with eight each in four Ampligen treatment arms and a placebo arm. Credit: Diana Polekhina on Unsplash.

AIM ImmunoTech has dosed the first healthy participants in a Phase I clinical study of its Ampligen drug as a potential intranasal prophylaxis or early-stage treatment for Covid-19 and other respiratory viral diseases.

The clinical study, titled ‘A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects’, is being conducted by the Centre for Human Drug Research (CHDR) institute in the Netherlands.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study intends to enrol a total of 40 healthy participants with eight each in four Ampligen treatment arms and a placebo arm.

Funded by AIM ImmunoTech, it is designed to evaluate the safety, tolerability, and biological activity of a repeated administration of intranasal Ampligen.

Participants will be given intranasal dosing every other day for a total of 13 days and seven doses.

According to a previous in vitro modelling at The Institute for Antiviral Research at Utah State University, Ampligen demonstrated to lower SARS-CoV-2 infectious viral yields by 90% at clinically achievable intranasal Ampligen dosage levels.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AIM ImmunoTech CEO Thomas Equels said: “We greatly appreciate the tremendous efforts of the entire team at CHDR to help us initiate our Phase 1 study of Ampligen as a potential intranasal therapy.

“Our objective is to expedite the development of Ampligen as potential prophylaxis or treatment for Covid-19.

“Prior results of in vitro modelling were promising, and we are highly encouraged by the potential of an intranasal prophylactic approach using Ampligen to prevent infection and spread of Covid-19.”

Last month, AIM received approval from the required Ethics Committee in the Netherlands to initiate the Phase I clinical study of Ampligen as an intranasal therapy.